Twitxy Saved

Pythia Labs

Verified account This account is verified. Learn more

@PythiaLabs

Pythia Labs builds frontier AI models for therapeutic discovery. We are beginning with next-generation antibodies for hard-to-drug targets.
Los Angeles, California pythialabs.com Joined June 2021
80 Following 109 Followers 4 Posts

Latest posts 2

Pythia Labs Verified account @PythiaLabs
We built Pythia-1, a frontier generative model for therapeutic discovery, to expand the reach of antibody therapeutics to hard-to-drug targets.

In our latest study, we used it to design full-length human antibodies that activate or inhibit GPCRs in cells. To our knowledge, a first for de novo design.

With just one design round and minimal screening, we identified multiple antagonists with single-digit nM inhibitory potency and an agonist with potency comparable to the receptor's natural ligand.

Designed antibodies also demonstrated favorable developability profiles.

Read the preprint: biorxiv.org/content/10.648…

We're releasing the sequences: pythialabs.com
0:30
1 replies 10 reposts 45 likes 315K views View on X
Pythia Labs Verified account @PythiaLabs
Design of Full-Length Agonist and Antagonist Antibodies for Hard Targets
Joshua Laniado Verified account @joshlaniado Oct 27
Introducing Pythia-1, a frontier generative model for protein design.

In our new study, we used it to rapidly design full-length human agonist and antagonist antibodies for hard-to-drug targets.

We’re sharing complete sequences of all lead antibodies to support independent validation and further research. 1/8
View quoted post on X